Corrigendum: Chronic Stress: Impacts on Tumor Microenvironment and Implications for Anti-Cancer Treatments(Front. Cell Dev. Biol., (2021), 9, (777018), 10.3389/fcell.2021.777018)

Abstract

In the original article, there were some mistakes in Figure 1 as published. 1) In the right part of Figure 1, “PD-L1” should be “PD-1”. 2) In the right part of Figure 1, “ITM-3” should be “TIM-3”. 3) In the right part of Figure 1, “dedective” should be “defective”. The corrected Figure 1 appears below. In the original article, there was an error in the section, Anti-Cancer Treatments and Interventions Targeting Chronic Stress, β-Blocker. “The combination of propranolol and immune checkpoint inhibitors may improve the efficacy of immunotherapy.” should be “The combination of propranolol with targeted therapy may improve the efficacy.”, as the following part talks about targeted therapy. A correction has been made to Anti-Cancer Treatments and Interventions Targeting Chronic Stress, β-Blocker, Paragraph 3: “The combination of propranolol with targeted therapy may improve the efficacy. An exploratory analysis of the LUX-Lung3 study revealed a significant PFS prolongation of NSCLC patients taking β-blockers with EGFR-TKI afatinib compared with those taking afatinib alone (median 11.1 vs. 6.9 months, p = 0.0001), indicating there is a synergic effect combining β-blockers with anti-EGFR therapy (Nilsson et al., 2017)”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.